查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587615

到 2030 年韓特氏症治療市場預測：按治療類型、併發症類型、給藥途徑、嚴重程度、最終用戶和地區進行的全球分析

Hunter Syndrome Treatment Market Forecasts to 2030 - Global Analysis By Treatment Type, Complication Type, Route of Administration, Severity, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2024 年全球韓特氏症治療市場規模為 13 億美元，預計在預測期內將以 7.3% 的複合年成長率成長，並在 2030 年達到 19 億美元。

韓特氏症是一種罕見的遺傳性疾病，由艾杜醣醛酸-2-硫酸酯酶缺乏引起，會導致進行性健康問題。治療主要著重於控制症狀和改善生活品質。酵素替代療法（ERT）是最常見的方法，其中向患者提供缺乏的酶以減少基材積累。其他治療包括維持運動功能的物理治療、解決呼吸困難的呼吸護理以及解決整形外科問題和支持器官功能的手術干預。

根據遺傳和罕見疾病資訊中心（GARD）統計，估計有 7,000 種罕見疾病，在美國受這些罕見疾病影響的總人數為 25 至 3000 萬人。

對韓特氏症的認知不斷提高

對韓特氏症的認知不斷提高，透過促進早期診斷和更深入地了解疾病，正在重塑治療市場。加強醫療保健專業人員和倡導團體的教育正在推動對酵素替代療法 (ERT) 等創新治療方法的需求。這種認可將促進相關人員之間的合作，改善患者的支持和結果，並最終擴大治療選擇並改善受疾病影響的人們的整體狀況。

缺乏熟練的專業人員

市場上缺乏熟練的專業人員是一個重大挑戰，導致診斷延遲和患者治療效果不佳。缺乏專業知識可能會阻礙酵素替代療法和基因療法等創新治療方法的有效實施。這種短缺限制了獲得專門治療的機會，並降低了患者支持和整體護理品質。結果，健康差距加劇，改善該疾病患者預後的潛力也降低。

醫療保健支出增加

市場醫療保健支出的增加反映了對先進治療和全面護理的需求不斷成長。隨著認知的提高，對酵素替代療法（ERT）和基因療法的投資將會擴大，與研究、開發和患者管理相關的成本將會增加。支出的激增可能會給旨在改善治療機會和結果的醫療保健預算帶來壓力。最終，它強調需要永續資金籌措和創新方法來有效支持受影響的人。

新興市場認知度低

新興市場對韓特氏症的認知不足阻礙了治療，導致診斷延遲和獲得治療的機會不足。許多醫療保健提供者缺乏對這種疾病的了解，這可能導致誤診或診斷不足。這一差距限制了創新治療方法的獲得，並最終影響患者的治療結果。加強教育和宣傳對於提高對這些地區受影響人群的認知和支持至關重要。

COVID-19 的影響：

COVID-19 大流行擾亂了醫療保健服務並限制了獲得基本治療方法，從而對市場產生了負面影響。常規就診被推遲，導致許多患者的診斷和治療開始延遲。此外，供應鏈中斷也影響了酵素替代療法的可用性。對大流行應對的關注已經將資源從罕見疾病上轉移出來，這凸顯了建立有彈性的醫療保健系統的必要性，該系統優先考慮為患有韓特氏症等罕見疾病的患者提供連續性護理。

預計在預測期內，肌肉骨骼部分將是最大的。

預計肌肉骨骼領域在預測期內將佔據最大的市場佔有率。患者可能需要物理治療、整形外科手術和疼痛管理策略等干涉措施來解決這些併發症。隨著我們對肌肉骨骼疾病的了解不斷加深，對專業治療和多學科護理方法的需求不斷成長。有效的管理對於改善患者的生活品質和整體功能結果至關重要。

預計診斷中心產業在預測期內複合年成長率最高

預計診斷中心產業在預測期內將呈現最高的複合年成長率。先進的測試方法，包括基因測試和酶測定，對於確認這種疾病至關重要。加強診斷中心和醫療保健提供者之間的合作將提高意識並促進及時介入。隨著越來越多的中心專注於罕見遺傳疾病，它們將有助於改善患者的治療效果，增加獲得標靶治療的機會，並最終改善受影響者的護理。

比最大的地區

預計北美地區在預測期內將佔據最大的市場佔有率。酵素替代療法 (ERT) 透過持續的臨床研究和患者宣傳工作正在獲得支持。獲得專業治療和診斷服務的機會正在改善，但在費用和保險範圍方面仍然存在挑戰。醫療保健提供者、製藥公司和倡導團體之間的合作對於改善該地區患者的治療效果至關重要。

複合年成長率最高的地區：

由於遺傳病患病率不斷上升，預計亞太地區在預測期內將出現最高的成長率。該市場的特點是治療方式多種多樣，包括 ERT、幹細胞移植和手術干預，但 ERT 由於其在控制關節活動度和臉部粗糙等症狀方面的有效性而目前佔據主導地位。日本和中國等國家在這一領域處於領先地位，受益於早期診斷和對罕見疾病認知的提高。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭標基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球韓特氏症治療市場：依治療類型

  • 酵素替代療法（ERT）
  • 造血幹細胞移植（HSCT）
  • 基因治療
  • 其他類型的治療

第6章韓特氏症治療的全球市場：依併發症類型

  • 心血管
  • 呼吸系統
  • 肌肉骨骼
  • 神經學的
  • 眼科
  • 肝
  • 腎
  • 血液學
  • 其他併發症類型

第7章全球韓特氏症治療市場：依給藥途徑

  • 靜脈注射 (IV)
  • 腦室內 (ICV)

第8章全球韓特氏症治療市場：依嚴重程度

  • 溫和的
  • 緩和
  • 嚴重

第9章全球韓特氏症治療市場：依最終用戶分類

  • 醫院
  • 診斷中心
  • 專科診所
  • 居家照護環境
  • 其他最終用戶

第10章全球韓特氏症治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章 公司概況

  • Takeda Pharmaceutical Company Limited
  • Medtronic
  • CANbridge Life Sciences Ltd.
  • Novartis AG
  • Zimmer Biomet
  • Sangamo Therapeutics
  • F. Hoffmann-La Roche Ltd
  • Jasper Therapeutics, Inc.
  • GSK Plc.
  • Denali Therapeutics
  • Abbott
  • JCR Pharmaceuticals Co., Ltd.
  • Bayer AG
  • Johnson & Johnson Services, Inc.
  • Stryker Corporation
Product Code: SMRC27600

According to Stratistics MRC, the Global Hunter Syndrome Treatment Market is accounted for $1.3 billion in 2024 and is expected to reach $1.9 billion by 2030 growing at a CAGR of 7.3% during the forecast period. Hunter Syndrome, a rare genetic disorder caused by a deficiency of the enzyme iduronate-2-sulfatase, leads to progressive health issues. Treatment primarily focuses on managing symptoms and improving quality of life. Enzyme replacement therapy (ERT) is the most common approach, providing patients with the missing enzyme to reduce substrate accumulation. Additional treatments may include physical therapy to maintain mobility, respiratory care to address breathing difficulties, and surgical interventions for orthopedic issues or organ function support.

According to the Genetic and Rare Diseases Information Center (GARD), there can be an estimated 7,000 rare diseases and the total number of individuals in the U.S. from these rare diseases can be 25-30 million.

Market Dynamics:

Driver:

Growing awareness of hunter syndrome

Growing awareness of Hunter Syndrome is reshaping the treatment market by promoting earlier diagnoses and a deeper understanding of the condition. Increased education among healthcare professionals and advocacy groups has spurred demand for innovative therapies, such as enzyme replacement therapy (ERT). This awareness fosters collaboration among stakeholders, enhancing patient support and outcomes, ultimately expanding treatment options and improving the overall landscape for those affected by the disorder.

Restraint:

Lack of skilled professionals

The lack of skilled professionals in the market poses significant challenges, leading to delayed diagnoses and suboptimal care for patients. Insufficient expertise can hinder effective implementation of innovative therapies, such as enzyme replacement and gene therapies. This shortage limits access to specialized treatment, reducing patient support and overall quality of care. Consequently, it exacerbates health disparities and diminishes the potential for improved outcomes in individuals affected by the disorder.

Opportunity:

Increased healthcare expenditure

Increased healthcare expenditure in the market reflects the rising demand for advanced therapies and comprehensive care. As awareness grows, investments in enzyme replacement therapy (ERT) and gene therapies expand, driving up costs associated with research, development, and patient management. This surge in spending aims to improve treatment accessibility and outcomes but may strain healthcare budgets. Ultimately, it highlights the need for sustainable funding and innovative approaches to support affected individuals effectively.

Threat:

Limited awareness in emerging markets

Limited awareness of Hunter Syndrome in emerging markets significantly hinders the treatment landscape, resulting in delayed diagnoses and inadequate access to care. Many healthcare providers may lack knowledge about the disorder, leading to misdiagnosis or underdiagnosis. This gap restricts the availability of innovative therapies ultimately impacting patient outcomes. Increased education and advocacy are essential to improve awareness and support for affected individuals in these regions.

Covid-19 Impact:

The COVID-19 pandemic adversely impacted the market by disrupting healthcare services and limiting access to essential therapies. Routine medical visits were postponed, delaying diagnoses and treatment initiation for many patients. Additionally, supply chain disruptions affected the availability of enzyme replacement therapies. The focus on pandemic response shifted resources away from rare diseases, highlighting the need for resilient healthcare systems that prioritize continuity of care for patients with rare conditions like Hunter Syndrome.

The musculoskeletal segment is projected to be the largest during the forecast period

The musculoskeletal segment is projected to account for the largest market share during the projection period. Patients may require interventions such as physical therapy, orthopedic surgeries, and pain management strategies to address these complications. The growing understanding of musculoskeletal manifestations drives demand for specialized treatments and multidisciplinary care approaches. Effective management is crucial to improving patients' quality of life and overall functional outcomes.

The diagnostic centers segment is expected to have the highest CAGR during the forecast period

The diagnostic centers segment is expected to have the highest CAGR during the extrapolated period. Advanced testing methods, including genetic testing and enzyme assays, are essential for confirming the disorder. Increased collaboration between diagnostic centers and healthcare providers enhances awareness and promotes timely intervention. As more centers specialize in rare genetic disorders, they contribute to improved patient outcomes and better access to targeted therapies, ultimately advancing care for those affected.

Region with largest share:

North America region is projected to account for the largest market share during the forecast period. Enzyme replacement therapy (ERT) has gained traction, supported by ongoing clinical research and patient advocacy efforts. Access to specialized care and diagnostic services is improving, although challenges remain in terms of cost and insurance coverage. The collaboration among healthcare providers, pharmaceutical companies, and advocacy groups is crucial for enhancing patient outcomes in the region.

Region with highest CAGR:

Asia Pacific is expected to register the highest growth rate over the forecast period due to increasing prevalence of genetic disorders. The market is characterized by diverse treatment modalities, including ERT, stem cell transplants, and surgical interventions, with ERT currently dominating due to its efficacy in managing symptoms like joint mobility and facial coarseness. Countries such as Japan and China are leading the charge, benefiting from early diagnosis and increased awareness of rare diseases.

Key players in the market

Some of the key players in Hunter Syndrome Treatment market include Takeda Pharmaceutical Company Limited, Medtronic, CANbridge Life Sciences Ltd., Novartis AG, Zimmer Biomet, Sangamo Therapeutics, F. Hoffmann-La Roche Ltd, Jasper Therapeutics, Inc., GSK Plc., Denali Therapeutics, Abbott, JCR Pharmaceuticals Co., Ltd. , Bayer AG, Johnson & Johnson Services, Inc. and Stryker Corporation.

Key Developments:

In September 2024, Denali Therapeutics announced plans to seek accelerated FDA approval for its investigational treatment, DNL310, to address Hunter syndrome (MPS II). Following productive discussions with the FDA, the company is set to submit a Biologics License Application (BLA) by early 2025.

In January 2024, Clinigen Group plc announced that it had received manufacturing and marketing approval for Hunterase (Disulfate-beta) ICV 15mg, under its strategic alliance with GC Pharma in Japan. This approval may help the company to acquire an enhanced customer base.

Treatment Types Covered:

  • Enzyme Replacement Therapy (ERT)
  • Hematopoietic Stem Cell Transplant (HSCT)
  • Gene Therapy
  • Other Treatment Types

Complication Types Covered:

  • Cardiovascular
  • Respiratory
  • Musculoskeletal
  • Neurological
  • Ocular
  • Hepatic
  • Renal
  • Hematological
  • Other Complication Types

Route of Administration Covered:

  • Intravenous (IV)
  • Intracerebroventricular (ICV)

Severity Covered:

  • Mild
  • Moderate
  • Severe

End Users Covered:

  • Hospitals
  • Diagnostic Centers
  • Specialty Clinics
  • Homecare Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hunter Syndrome Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Enzyme Replacement Therapy (ERT)
  • 5.3 Hematopoietic Stem Cell Transplant (HSCT)
  • 5.4 Gene Therapy
  • 5.5 Other Treatment Types

6 Global Hunter Syndrome Treatment Market, By Complication Type

  • 6.1 Introduction
  • 6.2 Cardiovascular
  • 6.3 Respiratory
  • 6.4 Musculoskeletal
  • 6.5 Neurological
  • 6.6 Ocular
  • 6.7 Hepatic
  • 6.8 Renal
  • 6.9 Hematological
  • 6.10 Other Complication Types

7 Global Hunter Syndrome Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Intravenous (IV)
  • 7.3 Intracerebroventricular (ICV)

8 Global Hunter Syndrome Treatment Market, By Severity

  • 8.1 Introduction
  • 8.2 Mild
  • 8.3 Moderate
  • 8.4 Severe

9 Global Hunter Syndrome Treatment Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Diagnostic Centers
  • 9.4 Specialty Clinics
  • 9.5 Homecare Settings
  • 9.6 Other End Users

10 Global Hunter Syndrome Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Takeda Pharmaceutical Company Limited
  • 12.2 Medtronic
  • 12.3 CANbridge Life Sciences Ltd.
  • 12.4 Novartis AG
  • 12.5 Zimmer Biomet
  • 12.6 Sangamo Therapeutics
  • 12.7 F. Hoffmann-La Roche Ltd
  • 12.8 Jasper Therapeutics, Inc.
  • 12.9 GSK Plc.
  • 12.10 Denali Therapeutics
  • 12.11 Abbott
  • 12.12 JCR Pharmaceuticals Co., Ltd.
  • 12.13 Bayer AG
  • 12.14 Johnson & Johnson Services, Inc.
  • 12.15 Stryker Corporation

List of Tables

  • Table 1 Global Hunter Syndrome Treatment Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Hunter Syndrome Treatment Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 3 Global Hunter Syndrome Treatment Market Outlook, By Enzyme Replacement Therapy (ERT) (2022-2030) ($MN)
  • Table 4 Global Hunter Syndrome Treatment Market Outlook, By Hematopoietic Stem Cell Transplant (HSCT) (2022-2030) ($MN)
  • Table 5 Global Hunter Syndrome Treatment Market Outlook, By Gene Therapy (2022-2030) ($MN)
  • Table 6 Global Hunter Syndrome Treatment Market Outlook, By Other Treatment Types (2022-2030) ($MN)
  • Table 7 Global Hunter Syndrome Treatment Market Outlook, By Complication Type (2022-2030) ($MN)
  • Table 8 Global Hunter Syndrome Treatment Market Outlook, By Cardiovascular (2022-2030) ($MN)
  • Table 9 Global Hunter Syndrome Treatment Market Outlook, By Respiratory (2022-2030) ($MN)
  • Table 10 Global Hunter Syndrome Treatment Market Outlook, By Musculoskeletal (2022-2030) ($MN)
  • Table 11 Global Hunter Syndrome Treatment Market Outlook, By Neurological (2022-2030) ($MN)
  • Table 12 Global Hunter Syndrome Treatment Market Outlook, By Ocular (2022-2030) ($MN)
  • Table 13 Global Hunter Syndrome Treatment Market Outlook, By Hepatic (2022-2030) ($MN)
  • Table 14 Global Hunter Syndrome Treatment Market Outlook, By Renal (2022-2030) ($MN)
  • Table 15 Global Hunter Syndrome Treatment Market Outlook, By Hematological (2022-2030) ($MN)
  • Table 16 Global Hunter Syndrome Treatment Market Outlook, By Other Complication Types (2022-2030) ($MN)
  • Table 17 Global Hunter Syndrome Treatment Market Outlook, By Route of Administration (2022-2030) ($MN)
  • Table 18 Global Hunter Syndrome Treatment Market Outlook, By Intravenous (IV) (2022-2030) ($MN)
  • Table 19 Global Hunter Syndrome Treatment Market Outlook, By Intracerebroventricular (ICV) (2022-2030) ($MN)
  • Table 20 Global Hunter Syndrome Treatment Market Outlook, By Severity (2022-2030) ($MN)
  • Table 21 Global Hunter Syndrome Treatment Market Outlook, By Mild (2022-2030) ($MN)
  • Table 22 Global Hunter Syndrome Treatment Market Outlook, By Moderate (2022-2030) ($MN)
  • Table 23 Global Hunter Syndrome Treatment Market Outlook, By Severe (2022-2030) ($MN)
  • Table 24 Global Hunter Syndrome Treatment Market Outlook, By End User (2022-2030) ($MN)
  • Table 25 Global Hunter Syndrome Treatment Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 26 Global Hunter Syndrome Treatment Market Outlook, By Diagnostic Centers (2022-2030) ($MN)
  • Table 27 Global Hunter Syndrome Treatment Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 28 Global Hunter Syndrome Treatment Market Outlook, By Homecare Settings (2022-2030) ($MN)
  • Table 29 Global Hunter Syndrome Treatment Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.